Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325971 | 0.89 | AGBL2 (0.36) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL1531085 | 0.85 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL1531177 | 0.84 | GABRB3 (0.38) | CYP1A2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL13326046 | 0.82 | PTGS2 (0.35) | CYP1A2CYP3A4CYP2C19HPGDLMNA | |
| SCHEMBL13303524 | 0.81 | GAA (0.39) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL1531091 | 0.77 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL1531188 | 0.77 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL13325363 | 0.73 | DRD1 (0.31) | — | |
| SCHEMBL14051590 | 0.72 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL13326422 | 0.72 | DHODH (0.38) | CYP1A2CYP3A4CYP2C19HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292606-A1 | Pyrazole derivative, its intermediate, and herbicide containing the same as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100152443-A1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152443-A1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7700786-B2 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700786-B2 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700786-B2 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20050070441-A1 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1362852-A1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152443-A1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | CYP51A1, CYP4F11, WEE1 | CYP1A2 45/4885CYP3A4 16/4885CYP2C19 75/4885 |
| US-20050070441-A1 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | CYP51A1, CYP4F11, WEE1 | CYP1A2 45/4885CYP3A4 16/4885CYP2C19 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.